Compare Mesoblast Limited (MESO) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Transocean Ltd — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Transocean Ltd trades at $5.18 (market cap $5.56B). The key difference: Transocean Ltd is far larger — about 2.6× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | RIG | |
|---|---|---|
Market Cap | $2.17B | $5.56B |
Sector | Technology | Technology |
52-Week High | $20.96 | $7.58 |
52-Week Low | $12.88 | $2.64 |
Enterprise Value | $2.17B | $10.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Transocean Ltd. (RIG) trades at $5.02, down 2.33% on the day, reflecting a bearish technical trend. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion in revenue, with a negative net income margin of -66.79%. Recent news highlights a significant $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and generating synergies. Analyst consensus is mixed, with a $7.00 price target suggesting potential upside from current levels.
The outlook for RIG hinges on successful execution of its merger and contract backlog conversion to profitability. Opportunities include a strong $7 billion backlog and operational momentum, but risks persist from sustained net losses, high debt, and oil price volatility. Investors should weigh the potential for deleveraging and synergy benefits against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
